Research &
Clinical Trials
The team at Bay Area Retina Associates is currently conducting multiple Clinical Trials. Through this cutting edge research, we will help improve treatments for those suffering from retinal diseases.
Contact our Study Department at 925.265.4146 or email us at smanz@bayarearetina.com to learn more about our currently enrolling clinical studies that provide patients with access to the latest treatments for age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, and other retinal conditions.
Patient Perspective
on Clinical Trials
“My experience with the Studies Department has been very, very good. I come in and am seen almost immediately. The doctors have been communicative, and kept me informed. I responded almost immediately, and the gray I saw in my vision is almost completely gone.”
– Clinical Trials Patient, Gary T.
Clinical Trials
Contact our Study Department at 925.265.4146 or email us at smanz@bayarearetina.com to learn more about our currently enrolling clinical studies.
Participation in our trials is completely voluntary. Eligibility will be determined based on a screening process which varies depending on the trial. Find our Observational Clinical Trials and our Interventional Clinical Trials as well as our closed trials below:
Observational Clinical Trials
BHAM
Brain Health Assessment iPad survey for patients 65+ with dry or wet age-related macular degeneration (AMD)
NHOR
A natural history observation and registry study of patients with macular telangiectasia type 2 (MacTel). Patients added to a “Registry of Participants with MacTel Type 2” may agree to be contacted for inclusion in future clinical trials.
Interventional Clinical Trials
Phase IIB intravitreal injection of long-acting Sunitinib Malate Depot Formulation (GB-102) for the treatment of neovascular (“wet”) age-related macular degeneration (AMD)
AERIE
Phase I/II implant system with AR-13503 for the treatment of neovascular (“wet”) age-related macular degeneration (AMD) and diabetic macular edema (DME)
Phase III port delivery system implant with Ranibizumab for the treatment of neovascular (“wet”) age-related macular degeneration (AMD)
AVANTE
Phase II intravitreal injection of DE-122 in combination with Lucentis®️ for the treatment of neovascular (“wet”) age-related macular degeneration (AMD)
DERBY
Phase III intravitreal injection of APL-2 for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
FOCUS
Phase III subcutaneous (i.e. under the skin) injection of Semaglutide in addition to standard of care for the treatment of diabetic retinopathy in patients with type 2 diabetes
GALLEGO
Phase II intravitreal injection of FHTR2163/RO7171009 for the treatment of geographic atrophy (GA) secondary to neovascular (“wet”) age-related macular degeneration (AMD)
KINGFISHER
Phase III intravitreal injection of Brolucizumab for the treatment of diabetic macular edema (DME)
NTMT
Phase III implant system with Renexus®️ for the treatment of macular telangiectasia type 2 (MacTel)
PANDA
Phase III intravitreal injection of Conbercept for the treatment of neovascular (“wet”) age-related macular degeneration (AMD)
STAMP
Phase IIII study comparing the effectiveness of intravitreal anti-VEGF therapy vs. Ozurdex prior to cataract surgery in patients with pre-existing diabetic macular edema (DME)
Phase III intravitreal injection of Brolucizumab for the treatment of macular edema (ME) secondary to central retinal vein occlusion (CRVO)
Phase III intravitreal injection of Faricimab (RO6867461) for the treatment of diabetic macular edema (DME)
TOFU
Phase II intravitreal injection of RMB-007 for the treatment of neovascular (“wet”) age-related macular degeneration (AMD)
(link for Phase 1/2a SUSHI study with RMB-007)
Closed Clinical Trials
SPECTRI
OMASPECT
DRCR Protocols I, S, T
Boulevard
Stairway
Avenue
Vapor
Sushi
Sapphire